FDA Offers Fee Breaks to Struggling Small Device Makers
Published Date: 7/31/2025
Notice
Summary
Hey small medical device businesses! The FDA just updated the rules on how you can prove financial hardship to skip some registration fees. This new guidance explains what info you need to share and how the FDA will decide if you qualify—making it easier to save money and keep innovating.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Waiver for Registration Fee If Hardship
If you run a small medical device business, the FDA’s final guidance explains how the Agency will determine whether your firm is experiencing “financial hardship” that makes it eligible for a waiver of its registration fee. This guidance updates the prior guidance issued August 1, 2018 and says FDA will use the updated criteria to decide waiver eligibility.
Guidance Lists Information FDA Will Review
The guidance details what information the FDA intends to review and consider when deciding whether a small medical device business qualifies for a financial-hardship waiver. If you apply for the waiver, you will need to provide the information the guidance lists so FDA can make its determination.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2025-14459 — Order Granting Temporary Exemptive Relief, Pursuant to Section 36(a)(1) of the Securities Exchange Act of 1934, From Certain Aspects of Rule 10c-1a
The SEC is giving some temporary relief to folks who report securities loans under Rule 10c-1a, like brokers and financial firms. This means they get more time to meet certain reporting and public data-sharing deadlines, pushing back some key dates into 2026 and beyond. No money changes hands now, but this helps everyone get ready without rushing.
Next: 2025-14461 — Notice of Intent To Grant a Joint Ownership Agreement With an Exclusive Patent License
The Air Force plans to team up with SkyHigh Ventures, LLC by sharing ownership and giving them exclusive rights to a new patent. This means SkyHigh can use and develop the invention, possibly bringing cool tech to life faster. If you’re involved in tech or business, keep an eye out—this deal could shake things up soon!